Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-03-31 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 | 2015-09-30 | 2014-09-30 | 2013-09-30 | 2012-09-30 | 2011-09-30 | 2010-09-30 | 2009-09-30 | 2008-09-30 | 2007-09-30 | 2006-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $21.4B | $21.8B | $20.2B | $19.4B | $18.9B | $19.1B | $16.1B | $17.3B | $16.0B | $12.1B | $12.5B | $10.3B | $8.4B | $8.1B | $7.7B | $7.6B | $7.1B | $7.0B | $7.1B | $6.4B | $5.7B |
| Bruttoergebnis | $9.9B | $9.9B | $9.1B | $8.2B | $8.5B | $8.6B | $6.8B | $8.3B | $7.3B | $6.0B | $6.0B | $4.7B | $4.3B | $4.2B | $4.0B | $4.0B | $3.7B | $3.7B | $3.6B | $3.3B | $2.9B |
| Bruttomarge % | 46.5% | 45.4% | 45.2% | 42.2% | 44.9% | 45.1% | 42.3% | 47.9% | 45.5% | 49.3% | 48.0% | 45.7% | 50.9% | 51.8% | 51.3% | 52.2% | 51.9% | 52.6% | 51.3% | 51.7% | 51.3% |
| Betriebsergebnis (EBIT) | $2.3B | $2.6B | $2.4B | $2.1B | $2.3B | $2.2B | $912M | $1.8B | $1.5B | $1.5B | $1.4B | $1.1B | $1.6B | $1.3B | $1.6B | $1.7B | $1.6B | $1.6B | $1.5B | $1.2B | $1.1B |
| Operative Marge % | 10.6% | 11.8% | 11.9% | 10.9% | 12.1% | 11.8% | 5.7% | 10.2% | 9.4% | 12.6% | 11.5% | 10.4% | 19.0% | 15.6% | 20.2% | 22.0% | 22.2% | 22.8% | 21.7% | 18.9% | 19.9% |
| Jahresüberschuss | $1.1B | $1.7B | $1.7B | $1.5B | $1.8B | $2.1B | $874M | $1.2B | $311M | $1.1B | $976M | $695M | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B | $1.2B | $1.1B | $890M | $752M |
| Nettomarge % | 5.3% | 7.7% | 8.5% | 7.7% | 9.4% | 10.9% | 5.4% | 7.1% | 1.9% | 9.1% | 7.8% | 6.8% | 14.0% | 16.1% | 15.2% | 16.8% | 18.5% | 17.6% | 15.9% | 14.0% | 13.1% |
| EBITDA | $4.7B | $5.0B | $4.8B | $4.4B | $4.4B | $4.4B | $3.1B | $4.1B | $3.9B | $2.6B | $2.6B | $2.0B | $2.2B | $1.8B | $2.1B | $2.2B | $2.1B | $2.1B | $2.1B | $1.8B | $1.6B |
| Ergebnis je Aktie (EPS) | $3.94 | $5.84 | $5.86 | $5.15 | $6.19 | $7.16 | $3.09 | $4.49 | $1.18 | $4.92 | $4.49 | $3.35 | $5.99 | $6.49 | $5.59 | $5.62 | $5.49 | $4.99 | $4.46 | $3.49 | $2.93 |
| Ausstehende Aktien (Mio.) | 281M | 287M | 291M | 288M | 287M | 292M | 282M | 275M | 265M | 224M | 218M | 208M | 198M | 199M | 209M | 226M | 240M | 247M | 253M | 255M | 257M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für BDX. /companies/us/BDX
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms